RGEN - Repligen Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
http://www.repligen.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees761

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony J. HuntCEO, Pres, Director & Member of Scientific Advisory Board985k488.68k1964
Mr. Jon K. SnodgresCFO & Sec.427.75k1.15M1966
Mr. Ralf KuriyelSr. VP of R&D504.2kN/A1959
Mr. Steve CurranVP of Global OperationsN/AN/AN/A
Ms. Sondra S. NewmanGlobal Head of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Repligen Corporation’s ISS Governance QualityScore as of December 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.